Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-049536
Filing Date
2025-11-05
Accepted
2025-11-05 16:08:35
Documents
81
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q dvax-20250930.htm   iXBRL 10-Q 1711402
2 EX-31.1 dvax-20250930xex311.htm EX-31.1 10347
3 EX-31.2 dvax-20250930xex312.htm EX-31.2 10679
4 EX-32.1 dvax-20250930xex321.htm EX-32.1 6109
5 EX-32.2 dvax-20250930xex322.htm EX-32.2 6093
  Complete submission text file 0001628280-25-049536.txt   8765274

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dvax-20250930.xsd EX-101.SCH 59306
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dvax-20250930_cal.xml EX-101.CAL 90674
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dvax-20250930_def.xml EX-101.DEF 272766
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dvax-20250930_lab.xml EX-101.LAB 744670
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dvax-20250930_pre.xml EX-101.PRE 525281
84 EXTRACTED XBRL INSTANCE DOCUMENT dvax-20250930_htm.xml XML 1296553
Mailing Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34207 | Film No.: 251453983
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)